Hepatitis B Virus (HBV) Replication During Tenofovir Therapy Is Frequent in Human Immunodeficiency Virus/HBV Coinfection
- PMID: 36242550
- DOI: 10.1093/cid/ciac823
Hepatitis B Virus (HBV) Replication During Tenofovir Therapy Is Frequent in Human Immunodeficiency Virus/HBV Coinfection
Abstract
In the Swiss HIV Cohort Study, 61 of 222 (27%) HIV-suppressed persons with chronic hepatitis B virus (HBV) infection had HBV replication after 2 years on tenofovir, of whom 77% were suppressed thereafter. Self-reported adherence to therapy and HBV viral load at tenofovir initiation were predictors of persistent replication.
Keywords: coinfection; hepatitis B virus; human immunodeficiency virus; tenofovir; viral replication.
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Conflict of interest statement
Potential conflicts of interest . E. H. reports support for attending meetings and/or travel from Gilead Sciences and ViiV Healthcare (paid to institution). B. S. reports a grant from Institutional Grant Inselspital Bern, support for attending meetings and/or travel from Gilead Sciences and ViiV Healthcare (paid to institution), and participation on a data and safety monitoring board (DSMB) or advisory board for Gilead Sciences (paid to institution). H. F. G. reports grants from National Institute of Health (NIH) and the Yvonne Jacob Foundation; an unrestricted research grant from Gilead Sciences (paid to institution); and participation on a DSMB or advisory board for Merck, Gilead Sciences, Janssen, ViiV Healthcare, GSK, and Novartis (paid to author). M. S. reports participation on a DSMB or advisory board for Gilead Sciences, ViiV Healthcare, Moderna, MSD, and Pfizer. E. B. reports grants or contracts from Merck Sharp and Dohme (paid to institution); support for attending meetings and/or travel from AbbVie, Gilead Sciences, Merck Sharp and Dohme, Pfizer AG, and ViiV Healthcare (paid to institution); and participation on a DSMB or advisory board for Gilead Sciences, Merck Sharp and Dohme, Pfizer AG, ViiV Healthcare, Ely Lilly, and Astra Zeneca (Paid to institution). P. S. has received consulting/advisory board membership fees from Gilead Sciences. A. C. reports grants from Gilead Sciences, ViiV Healthcare, MSD (unrestricted educational grant; Groupe LIPO et métabolisme; grant to institution), and MSD (research grant). A. R. reports serving on advisory boards for Gilead Sciences and MSD (paid to institution), travel grants from Gilead Sciences and Pfizer, and research support by an investigator-initiated trial grant from Gilead Sciences (all renumeration went to institution). G. W. reports grants or contracts from Gilead Sciences and Roche Diagnostics (paid to institution); payment or honoraria for lectures, presentations, speakers and bureaus, manuscript writing, or educational events from Gilead Sciences and MSD (paid to institution). All remaining authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
